Acadia Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California, with an additional East Coast headquarters in Princeton, New Jersey. The company's core business is dedicated to the development and commercialization of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. Its mission is to translate scientific promise into meaningful innovation that improves the lives of patients within these underserved communities globally.

Acadia's commercial portfolio includes two FDA-approved treatments: NUPLAZID (pimavanserin), which is indicated for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis, and DAYBUE (trofinetide), approved for the treatment of Rett syndrome. The company maintains a robust and diverse pipeline, with mid- to late-stage programs targeting conditions such as Alzheimer's disease psychosis and Lewy body dementia psychosis, alongside earlier-stage programs addressing other neurological and rare disease needs.

In recent news, the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in June 2026, recommending marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in the European Union, reversing an earlier negative opinion. This recommendation, if approved by the European Commission, would make DAYBU the first approved therapy for this indication in the EU. Catherine Owen Adams assumed the role of Chief Executive Officer in September 2024, leading the company's strategic vision and continued focus on advancing therapies for patients with neurological disorders and rare diseases.